Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE On Alimta, Pixuvri Ups Concerns It Prefers Cost Over Clinical Efficacy

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE’s tentative nod to CTI’s Pixuvri for NHL and refusal to grant an indication extension to Lilly’s Alimta could spark industry concern that the agency favors lower cost over clinical effectiveness.


Related Content

U.K. Coverage Rejection Of Alimta In NSCLC Increases Concerns About Access To Cancer Drugs
CTI Finds Pixuvri’s Conditional Authorization Is Not Enough To Win NICE Approval
U.K.'s Controversial NICE Suspends Publication Of Guidances Until After General Election
Lilly’s Alimta Gets UK Recommendation As Mesothelioma Therapy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts